Cargando…

The differential effects of statins on the metastatic behaviour of prostate cancer

BACKGROUND: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown. METHODS: Bone marrow s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, M, Hart, C, Tawadros, T, Ramani, V, Sangar, V, Lau, M, Clarke, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349174/ https://www.ncbi.nlm.nih.gov/pubmed/22531631 http://dx.doi.org/10.1038/bjc.2012.138

Ejemplares similares

Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells
por: Tawadros, T, et al.
Publicado: (2012)

Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer
por: Brown, M, et al.
Publicado: (2014)

Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer
por: Brown, M D, et al.
Publicado: (2010)

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
por: Maddineni, S B, et al.
Publicado: (2005)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease
por: Darby, S, et al.
Publicado: (2009)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β(3) affinity modulation
por: Goc, A, et al.
Publicado: (2012)

A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei
por: Bibi, R, et al.
Publicado: (2006)

Impact of differential cyclin D1 expression and localisation in prostate cancer
por: Comstock, C E S, et al.
Publicado: (2007)

Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6
por: Schmitt, J, et al.
Publicado: (2014)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer
por: Balanathan, P, et al.
Publicado: (2009)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer
por: Kachroo, N, et al.
Publicado: (2013)

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials
por: Som, A, et al.
Publicado: (2012)

EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205
por: Massoner, P, et al.
Publicado: (2014)

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer
por: Palmieri, C, et al.
Publicado: (2013)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2010)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

HIF-1α determines the metastatic potential of gastric cancer cells
por: Rohwer, N, et al.
Publicado: (2009)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study
por: Larkin, S E T, et al.
Publicado: (2016)

Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system
por: Wheeler, S E, et al.
Publicado: (2014)

Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence
por: Truong, M, et al.
Publicado: (2012)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
por: Molinari, F, et al.
Publicado: (2009)

Study of matrix metalloproteinases and their inhibitors in prostate cancer
por: Escaff, S, et al.
Publicado: (2010)

Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion
por: Fry, Simon A, et al.
Publicado: (2016)

Identification of markers of prostate cancer progression using candidate gene expression
por: Larkin, S E T, et al.
Publicado: (2012)

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
por: Murata, A, et al.
Publicado: (2013)

The prognostic significance of vasohibin-1 expression in patients with prostate cancer
por: Kosaka, T, et al.
Publicado: (2013)

microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
por: Ueno, K, et al.
Publicado: (2013)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6fllfok16jgq9b1bdomfvuha6j